Continue secukinumab after prior study, without safety issues
Part of Immune system & allergy clinical trials.
This trial lets people who already did a previous secukinumab (an injection for certain inflammatory conditions) study continue treatment afterward. It’s mainly for people who are still getting benefit and can’t otherwise get the approved medication through their local system.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign consent (or get a parent/guardian permission for youth) before any study checks
- You must be able to talk with the study team and follow study instructions
- You previously completed a secukinumab treatment study with Novartis (or were not finished due to non-safety, non-efficacy reasons)
- Your doctor believes you’re still benefiting and the benefits are worth the risks
- You cannot get the regular (marketed) secukinumab through your local prescription or insurance/reimbursement rules
- You must not have stopped the earlier study treatment early
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called secukinumab (given through an IV) in children with juvenile psoriatic arthritis. The goal is to see how well it works and if it's safe over time, for up to 6 years.
This trial is testing the safety of a medicine called secukinumab in adults with axial spondyloarthritis (a type of inflammatory arthritis affecting the spine). It may be a good option if you have this condition and want to help researchers learn more about how safe this treatment is for Indian patients.
This trial studies whether secukinumab (a targeted medicine given by injection) can reduce symptoms and disease activity in adults with active ankylosing spondylitis. You may be considered if other common anti-inflammatory medicines have not worked well enough or you could not take them.
This study looks at how well secukinumab (Cosentyx) works over time for children with certain types of juvenile arthritis. It aims to understand the best treatment strategies and outcomes.
This study is looking at how well secukinumab works for people with ankylosing spondylitis in Korea who have never taken a biologic or JAK inhibitor before. It aims to understand if the drug helps control symptoms over a short period of time.
This study looks at patients with moderate-to-severe psoriasis who have already responded well to secukinumab (an injection that targets the immune system). Researchers want to see which maintenance dosing schedule works best long-term and causes the fewest side effects.
Hear when a new Autoimmunity, Inflammation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.